Table S1: HCV genotype and HCV treatment

	Overall n=179 (%)	Decompensated cirrhosis n=75 (%)	HCC n=104 (%)
HCV Genotype 1 2 3 4 5	102 (57.3) 7 (3.9) 41 (23.0) 26 (14.6) 2 (1.1)	45 (60.0) 5 (6.7) 12 (16.0) 12 (16.0) 1 (1.3)	57 (55.3) 2 (1.9) 29 (28.2) 14 (13.6) 1 (1.0)
Previous HCV treatment	133 (74.3)	55 (73.3)	78 (75.0)

Current HCV treatment
  Sofosbuvir
  Simeprevir
  Daclatasvir
  Ledispasvir
  Ribavirin
	
	179 (100.0)
	11 (6.2)
	111 (62.0)
	18 (10.1)
	96 (53.6)
		
		75 (100)
		2 (2.7)
		47 (62.7)
		10 (13.3)
		38 (50.7)
			
			104 (100)
			9 (8.7)
			64 (61.5)
			8 (7.7)
			58 (55.8)

HCV: hepatitis C virus; HCC: hepatocellular carcinoma

Table S2: Serious adverse events under DAA therapy for HCV

SAEs	n
Infection	9
Decompensation of ascites	1
Anemia	4
Variceal bleeding	3
Encephalopathy	3
Asthenia	5
Cramps	2
Psychological disorders	1
Bradycardia	1
Erythema	1
Pruritus	1
Not known	3

SAEs: Serious Adverse Events

Table S3: Prediction of delisting for an improvement in 75 patients listed for decompensated cirrhosis at baseline of HCV treatment

Scoring system	Cut-off point	Youden Index	Sensitivity(%)	Specificity(%)	PPV (%)	NPV (%)
MELD	10	0.241	37	87	50	80
	11	0.185	42	76	38	79
	12	0.324	58	75	44	84
	13	0.357	68	67	42	86
	14	0.424	84	58	41	91
	15	0.440	90	55	41	94
	16	0.295	90	40	34	92
	17	0.311	95	36	34	95
	18	0.202	95	26	31	93
	19	0.147	95	20	29	92
	20	0.129	95	18	29	91
	21	0.111	95	16	28	90
	22	0.038	95	9	27	83
	23	0.002	95	6	26	75
	24	0.055	100	6	29	100
Child-Pugh	5	0.121	21	91	44	77
	6	0.226	37	86	47	80
	7	0.416	68	73	46	87
	8	0.343	79	55	38	89
	9	0.324	84	48	36	90
	10	0.215	95	27	31	94
	11	0.161	100	16	29	100
	12	0.107	100	11	28	100
	13	0.018	100	2	26	100

MELD: Model for End-Stage Liver Disease; PPV: positive predictive value; NPV: negative predictive value.